Solid phase synthesis, NMR structure determination of ?-KTx3.8, its in silico docking to Kv1.x potassium channels, and electrophysiological analysis provide insights into toxin-channel selectivity.
 

Solid phase synthesis, NMR structure determination of ?-KTx3.8, its in silico docking to Kv1.x potassium channels, and electrophysiological analysis provide insights into toxin-channel selectivity.

Related Articles Solid phase synthesis, NMR structure determination of ?-KTx3.8, its in silico docking to Kv1.x potassium channels, and electrophysiological analysis provide insights into toxin-channel selectivity.

Toxicon. 2015 May 5;

Authors: Kohl B, Rothenberg I, Ali SA, Alam M, Seebohm G, Kalbacher H, Voelter W, Stoll R

Abstract
Animal venoms, such as those from scorpions, are a potent source for new pharmacological substances. In this study we have determined the structure of the ?-KTx3.8 (named as Bs6) scorpion toxin by multidimensional protonhomonuclear NMR spectroscopy and investigated its function by molecular dynamics (MD) simulations and electrophysiological measurements. Bs6 is a potent inhibitor of the Kv1.3 channel which plays an important role during the activation and proliferation of memory T-cells (TEM), which play an important role in autoimmune diseases. Therefore, it could be an interesting target for treatment of autoimmune diseases. In this study, Bs6 was synthesised by solid-phase synthesis and its three-dimensional (3D) structure has been determined. To gain a deeper insight into the interaction of Bs6 with different potassium channels like hKv1.1 and hKv1.3, the protein-protein complex was modelled based on known toxin-channel structures and tested for stability in MD simulations using GROMACS. The toxin-channel interaction was further analysed by electrophysiological measurements of different potassium channels like hKv1.3 and hKv7.1. As potassium channel inhibitors could play an important role to overcome autoimmune diseases like multiple sclerosis and type-1 diabetes mellitus, our data contribute to the understanding of the molecular mechanism of action and will ultimately help to develop new potent inhibitors in future.


PMID: 25953725 [PubMed - as supplied by publisher]



More...